[Two pediatric cases of anti-NMDA receptor antibody encephalitis]

Arch Pediatr. 2014 Nov;21(11):1216-9. doi: 10.1016/j.arcped.2014.08.020. Epub 2014 Oct 2.
[Article in French]

Abstract

Although less frequent than viral encephalitis, anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a frequent form of acute pediatric encephalitis. After a prodromal phase of flu-like symptoms, psychiatric symptoms predominate - agitation, anxiety, hallucinations - and can make correct diagnosis more difficult. Also noted are abnormal dyskinesia and dystonia-like movements, partial seizures, difficulties talking or memorizing, and autonomic manifestations. The presentation of two cases of anti-NMDAR encephalitis illustrates the symptoms of this disease. Although the CSF abnormalities are not highly specific of this disease, and MRI most often normal, EEG shows more specific signs. These observations enable us to discuss different treatment options and understand the progression of this disease.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis / diagnosis*
  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis / drug therapy
  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis / epidemiology
  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis / immunology*
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Autoantibodies / blood*
  • Brain / pathology
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • Diagnosis, Differential
  • Drug Therapy, Combination
  • Electroencephalography
  • Emergency Service, Hospital
  • Epilepsy, Tonic-Clonic / etiology
  • Female
  • France
  • Humans
  • Immunization, Passive
  • Magnetic Resonance Imaging
  • Male
  • Methylprednisolone / therapeutic use
  • Neurologic Examination
  • Predictive Value of Tests
  • Prodromal Symptoms
  • Receptors, N-Methyl-D-Aspartate / immunology*
  • Rituximab

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Autoantibodies
  • Receptors, N-Methyl-D-Aspartate
  • Rituximab
  • Methylprednisolone